Melodiol Global Health (CHIA:ME1DA) - Stock Price, News & Analysis

ME1DA Stock Overview

Engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific.

About the company

ME1DA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 18.8% per year over past 5 years

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

+ 1 more risk

Melodiol Global Health Limited Competitors

Invex Therapeutics

ASX:IXC

AU$5.6m

Firebrick Pharma

ASX:FRE

AU$10.7m

Cann Global

ASX:CGB

AU$5.4m

Rhinomed

ASX:RNO

AU$11.5m

Price History & Performance

Summary of all time highs, changes and price drops for Melodiol Global Health
Historical stock prices
Current Share Price	AU$0.014
52 Week High	AU$0.019
52 Week Low	AU$0.014
Beta	2.66
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-17.65%

Recent updates

Shareholder Returns

	ME1DA	AU Pharmaceuticals	AU Market
7D	-17.6%	5.6%	-0.008%
1Y	n/a	93.4%	15.0%

Return vs Industry: Insufficient data to determine how ME1DA performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ME1DA performed against the Australian Market.

Price Volatility

Is ME1DA's price volatile compared to industry and market?
ME1DA volatility
ME1DA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	8.7%
10% most volatile stocks in AU Market	16.7%
10% least volatile stocks in AU Market	3.6%

Stable Share Price: ME1DA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ME1DA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	n/a	Will Lay	melodiolglobalhealth.com

Melodiol Global Health Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, the Asia Pacific, the United States, and internationally. The company develops and commercializes therapeutic products; develops and sells beauty and personal care products under the Green Goo, Southern Butter, and Goodgoo brands; and cultivates, processes, and sells cannabis products. Its products include cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and minerals in a lozenge delivery system; the ImpACTIVE Pro Releaf Stick to provide relief to muscle aches, particularly in professional sport, and acts as an alternative to pharmacological solutions sold through online channels; Ritual Green, a dried flower; Ritual Sticks for pre-rolled joints; and Ritual Gold, a handheld vapouriser.

Melodiol Global Health Limited Fundamentals Summary

How do Melodiol Global Health's earnings and revenue compare to its market cap?
ME1DA fundamental statistics
Market cap	AU$3.42m
Earnings (TTM)	-AU$53.94m
Revenue (TTM)	AU$11.68m

0.3x

P/S Ratio

-0.1x

P/E Ratio

Is ME1DA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ME1DA income statement (TTM)
Revenue	AU$11.68m
Cost of Revenue	AU$14.02m
Gross Profit	-AU$2.34m
Other Expenses	AU$51.61m
Earnings	-AU$53.94m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.21
Gross Margin	-20.00%
Net Profit Margin	-461.80%
Debt/Equity Ratio	115.9%

How did ME1DA perform over the long term?

See historical performance and comparison

Melodiol Global Health CHIA:ME1DA Stock Report